Literature DB >> 23157629

Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology.

Donatella Marazziti1, Stefano Baroni, Franco Borsini, Michela Picchetti, Elena Vatteroni, Valentina Falaschi, Mario Catena-Dell'Osso.   

Abstract

The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop. A lot of controversies still exist regarding their binding affinity, effects of 5-HT6 ligands on brain catecholamines, behavioral syndromes regulated by them, and brain distribution. In spite of the lack of information on metabolic pattern of the various compounds, some of 5-HT6 receptor ligands entered the clinical development as potential anti-dementia, antipsychotic, antidepressant and anti-obese drugs. The present paper is a comprehensive review on the state of art of the 5-HT6 receptors, while highlighting the potential clinical applications of 5-HT6 receptor agonists/antagonists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23157629

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  Dynamics and structural determinants of ligand recognition of the 5-HT6 receptor.

Authors:  Márton Vass; Balázs Jójárt; Ferenc Bogár; Gábor Paragi; György M Keserű; Ákos Tarcsay
Journal:  J Comput Aided Mol Des       Date:  2015-11-16       Impact factor: 3.686

2.  Sulfonamide Derivatives and Pharmaceutical Applications Thereof.

Authors:  Benjamin Blass
Journal:  ACS Med Chem Lett       Date:  2015-12-30       Impact factor: 4.345

3.  Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.

Authors:  Ramakrishna Nirogi; Vinod Kumar Goyal; Vijay Benade; Ramkumar Subramanian; Jyothsna Ravula; Satish Jetta; Anil Shinde; Santosh Kumar Pandey; Pradeep Jayarajan; Venkat Jasti; Jeffrey Cummings
Journal:  Neurol Ther       Date:  2022-07-31

4.  Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.

Authors:  Ramakrishna Nirogi; John Ieni; Vinod Kumar Goyal; Jyothsna Ravula; Satish Jetta; Anil Shinde; Pradeep Jayarajan; Vijay Benade; Veera Raghava Chowdary Palacharla; Dhanunjay Kumar Dogiparti; Venkat Jasti; Alireza Atri; Jeffrey Cummings
Journal:  Alzheimers Dement (N Y)       Date:  2022-06-01

5.  Serotonin receptor 6 mediates defective brain development in monoamine oxidase A-deficient mouse embryos.

Authors:  Chi Chiu Wang; Gene Chi Wai Man; Ching Yan Chu; Astrid Borchert; Aslihan Ugun-Klusek; E Ellen Billett; Hartmut Kühn; Christoph Ufer
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

6.  Constitutive Activity of Serotonin Receptor 6 Regulates Human Cerebral Organoids Formation and Depression-like Behaviors.

Authors:  Qinying Wang; Xiaoxu Dong; Tingting Hu; Chao Qu; Jing Lu; Yue Zhou; Jinsong Li; Gang Pei
Journal:  Stem Cell Reports       Date:  2020-12-23       Impact factor: 7.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.